-
Macroeconomic Analysis
NewIceland PESTLE Insights – A Macroeconomic Outlook Report
Financial intermediation, real estate and business activities contributed 25.5% to the gross value added (GVA) in 2023, followed by the mining, manufacturing and utilities with 14.6%, and wholesale, retail and hotels with 11.9%. According to GlobalData estimates, the three sectors are expected to grow by 6.2%, 6.4% and 8.0%, respectively, in 2024. Reykjavik contributed 57.6% of Iceland’s GDP and was home to 60.8% of the country’s population as of 2023
-
Macroeconomic Analysis
NewVenezuela PESTLE Insights – A Macroeconomic Outlook Report
Mining, manufacturing and utilities activities contributed 45.9% to the gross value added (GVA) in 2023, followed by wholesale, retail and hotels (24.1%), and construction activities (2.4%), according to GlobalData estimates. According to OPEC, Venezuela has around 303.2 billion barrels of proven crude oil reserves, it produced 716,000 barrels of crude oil per day in 2022.
-
Macroeconomic Analysis
NewArgentina PESTLE Insights – A Macroeconomic Outlook Report
Mining, manufacturing and utilities activities contributed 24.0% to the gross value added (GVA) in 2023, followed by wholesale, retail and hotels activities (21.9%), financial intermediation, real estate and business activities(14.1%). In nominal terms, the three sectors are expected to grow by 61.9%, 61.9% and 61.0%, respectively, in 2024. Four major cities comprised 39.2% of the country’s population in 2023 and the highest concentration of economic activities are in Buenos Aires, the capital of Argentina, according to GlobalData.
-
Macroeconomic Analysis
NewBrazil PESTLE Insights – A Macroeconomic Outlook Report
Mining, manufacturing and utilities activities contributed 20.8% to the gross value added (GVA) in 2023, followed by financial intermediation, real estate and business activities (16.6%), wholesale, retail and hotels (14.2%). In nominal terms, the three sectors are expected to grow by 5.6%, 6.1% and 5.7%, respectively, in 2024. Sao Paulo, Rio de Janeiro, Belo Horizonte are the major cities of Brazil that contributed 27.3% to the country’s GDP and comprised 19.9% of the country’s population in 2023, according to the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Volrustomig in Hypopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Volrustomig in Hypopharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Volrustomig in Hypopharyngeal Cancer Drug Details: MEDI-5752 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Volrustomig in Laryngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Volrustomig in Laryngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Volrustomig in Laryngeal Cancer Drug Details: MEDI-5752 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Volrustomig in Oropharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Volrustomig in Oropharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Volrustomig in Oropharyngeal Cancer Drug Details: MEDI-5752 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Volrustomig in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Volrustomig in Cervical Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Volrustomig in Cervical Cancer Drug Details: MEDI-5752 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Volrustomig in Rhabdomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Volrustomig in Rhabdomyosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Volrustomig in Rhabdomyosarcoma Drug Details: MEDI-5752 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Volrustomig in Leiomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Volrustomig in Leiomyosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Volrustomig in Leiomyosarcoma Drug Details: MEDI-5752 is under development for the treatment of...